Literature DB >> 31516620

Dysregulation of the miRNA biogenesis components DICER1, DROSHA, DGCR8 and AGO2 in clear cell renal cell carcinoma in both a Korean cohort and the cancer genome atlas kidney clear cell carcinoma cohort.

Sang Su Lee1, Hyeonji Min2, Ji Yong Ha3, Byung Hoon Kim3, Mi Sun Choi4, Shin Kim2.   

Abstract

Impairment of microRNA (miRNA) biogenesis may be involved in clear cell renal cell carcinoma (ccRCC). The objective of the present study was to investigate the mRNA levels of important miRNA machinery components, DICER1, DROSHA, DiGeroge syndrome critical region gene 8 (DGCR8), and Argonaute 2 (AGO2), and their correlations with clinicopathological characteristics of ccRCC using mRNA expression data from The Cancer Genome Atlas kidney clear cell carcinoma (TCGA KIRC) cohort and a Korean ccRCC cohort. mRNA levels of DICER1, DROSHA, and DGCR8 were significantly decreased in both cohorts. However, AGO2 was significantly downregulated only in the Korean ccRCC cohort. Additionally, positive correlations were observed between the altered mRNA levels of DICER1 and DROSHA as well as DROSHA and DGCR8 in both cohorts. In the TCGA KIRC cohort, alterations in the mRNA levels of DICER1 were significantly correlated with histological grade. Furthermore, the altered mRNA levels of DGCR8 showed significant associations with sex and histologic grades. However, in the Korean ccRCC cohort, no factors were significantly associated with any clinicopathological parameters, including sex, age, T stage, Fuhrman grade/The International Society of Urological Pathology grade, lymphovascular invasion, and peri-renal fat invasion. Taken together, these findings indicate that DICER1, DROSHA, DGCR8 and AGO2 are significantly dysregulated in ccRCC, suggesting that they are important in the pathophysiology of this malignancy.

Entities:  

Keywords:  clear cell renal cell carcinoma; miRNA biogenesis; the cancer genome atlas

Year:  2019        PMID: 31516620      PMCID: PMC6732956          DOI: 10.3892/ol.2019.10759

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  7 in total

Review 1.  Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation.

Authors:  Zsuzsanna Gaál
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

Review 2.  From the Argonauts Mythological Sailors to the Argonautes RNA-Silencing Navigators: Their Emerging Roles in Human-Cell Pathologies.

Authors:  Vasiliki I Pantazopoulou; Stella Georgiou; Panos Kakoulidis; Stavroula N Giannakopoulou; Sofia Tseleni; Dimitrios J Stravopodis; Ema Anastasiadou
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

Review 3.  Regulatory Mechanism of MicroRNA Expression in Cancer.

Authors:  Zainab Ali Syeda; Siu Semar Saratu' Langden; Choijamts Munkhzul; Mihye Lee; Su Jung Song
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

Review 4.  microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis.

Authors:  Tiziana Annese; Roberto Tamma; Michelina De Giorgis; Domenico Ribatti
Journal:  Front Oncol       Date:  2020-11-27       Impact factor: 6.244

5.  MicroRNA Processing Pathway-Based Polygenic Score for Clear Cell Renal Cell Carcinoma in the Volga-Ural Region Populations of Eurasian Continent.

Authors:  Elizaveta Ivanova; Irina Gilyazova; Valentin Pavlov; Adel Izmailov; Galiya Gimalova; Alexandra Karunas; Inga Prokopenko; Elza Khusnutdinova
Journal:  Genes (Basel)       Date:  2022-07-20       Impact factor: 4.141

6.  The Drosha-Independent MicroRNA6778-5p/GSK3β Axis Mediates the Proliferation of Gastric Cancer Cells.

Authors:  Mingjun Ren; Li Xing; Wanping Wang; Wanying Bi; Wanjun Wu; Gui Jiang; Weiji Wang; Xingdong Liang; Manran Liu; Shifu Tang
Journal:  Comput Intell Neurosci       Date:  2022-09-30

7.  Circular RNA profiling identifies circ102049 as a key regulator of colorectal liver metastasis.

Authors:  Qiaoming Zhi; Daiwei Wan; Rui Ren; Zhihua Xu; Xiaobo Guo; Ye Han; Fei Liu; Ye Xu; Lei Qin; Yilin Wang
Journal:  Mol Oncol       Date:  2020-12-29       Impact factor: 7.449

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.